Abstract: A chromosomal DNA sequence which codes for human lymphotoxin, a lymphotoxin expression vector which contains a DNA sequence wherein a chromosomal DNA sequence coding for human lymphotoxin and promoter region which functions in animal cell are linked together, lymphotoxin resistant cell line, transformed animal cell culture which is formed by transforming cultured animal cell with a lymphotoxin expression vector which contains a chromosomal DNA sequence coding for human lymphotoxin and, a process for preparing human lymphotoxin, which comprises transforming cultured animal cell with a lymphotoxin expression vector which contains a chromosomal DNA sequence coding for human lymphotoxin, culturing the transformed cell culture to produce human lymphotoxin, and collecting the human lymphotoxin.According to the present invention, LT which is expected for application as the antitumor agent can be produced effectively in a large amount.

Abstract: A DNA sequence on which a chromosomal DNA sequence coding for human interferon-.gamma. (HuIFN-.gamma.) and having a TATA box is ligated to a sequence of a promoter. Cell cultures transformed with said DNA revealed a higher expression of HuIFN- than cell cultures transformed with a DNA which does not have such TATA box. When transformed with said DNA, cell cultures produced HuIFN-.gamma. in a serum free medium. Transformed cell cultures derived from blood cells of HuIFN-.gamma. resistant human cell-line also could produce HuIFN-.gamma..

Abstract: Novel 7-hydroxyguanine compounds of the formula: ##STR1## wherein R is hydrogen atom or hydroxy, and a salt thereof, which have excellent anti-tumor activity, process for preparing the compounds, and anti-tumor agent containing said compound as an active ingredient.

Abstract: Novel 7-hydroxyguanine compounds of the formula: ##STR1## wherein R is hydrogen atom, tetrahydropyranyl group or tetrahydrofuryl group, and R.sub.2 is hydrogen atom, tetrahydropyranyl group or tetrahydrofuryl group, provided that when R.sub.1 is hydrogen atom, R.sub.2 is tetrahydropyranyl group or tetrahydrofuryl group, and a salt thereof, which have excellent anti-tumor activity, process for preparing the compounds, and anti-tumor agent containing said compound as an active ingredient.

Abstract: A process for preparing the optically active oxazolidinone derivative [(S)-I] by utilizing microorganisms or enzymes having a stereoselective esterase activity capable of asymmetrically hydrolyzing the racemates of the acyloxyoxazolidinone derivative [(R,S)-II], by separating the unreacted compound [(S)-II] from the hydrolyzed compound [(R)-I] and by hydrolyzing the compound [(S)-II]. The compounds are useful as intermediates for preparing optically active .beta.-adrenergic blocking agents.

Abstract: A process for producing D-.beta.-hydroxyalkanoic acids by utilizing microorganisms having an ability of stereospecifically converting alkanoic acids, 2-alkenoic acids or alcohols into D-.beta.-hydroxyalkanoic acids.

Abstract: A process is disclosed wherein coenzyme Q is prepared from tissues of animals and plants or microbial cells by treating a water suspension of said materials with an alkali, or with an acid and then an alkali, and by extracting the treated suspension with at least one water-immiscible organic solvent followed by recovery of coenzyme Q from the extract.

Abstract: A process is disclosed in which an optically active monoalkyl ester of .beta.-(S)-aminoglutaric acid is prepared by subjecting a dialkyl ester of .beta.-protected aminoglutaric acid to the action of a culture broth, cells, or treated cells of a microorganism capable of stereoselectively hydrolyzing only one of the ester groups in the above-mentioned dialkyl ester to produce an optically active monoalkyl ester of .beta.-protected (S)-aminoglutaric acid, and then removing the amino-protecting group from the product. An optically active monoalkyl ester of .beta.-(S)-aminoglutaric acid is useful as a starting material for synthesizing .beta.-lactam antibiotics of carbapenem type such as thienamycin.

Abstract: A stable composition of S-adenosyl-L-methionine is disclosed which includes a salt of S-adenosyl-L-methionine and a pharmaceutically acceptable, water-soluble salt of a bivalent or trivalent metal. The salt of S-adenosyl-L-methionine is, for example, a salt of S-adenosyl-L-methionine with hydrochloric acid, sulfuric acid, p-toluenesulfonic acid, phosphoric acid, formic acid, acetic acid, citric acid, tartaric acid, or maleic acid; or a double salt of S-adenosyl-L-methionine with the foregoing acids. The salt of a bivalent or trivalent metal is, for example, calcium chloride, ferric chloride, magnesium chloride, or magnesium sulfate. A process for preparing the composition is also disclosed. The composition is suitable for preparing pharmaceutical preparations of S-adenosyl-L-methionine.

Abstract: A process is disclosed wherein D(-)-.beta.-hydroxyisobutyric acid is produced fermentatively from isobutyric acid or methacrylic acid by the stereoselective action of microorganisms having the ability to convert isobutyric acid or methacrylic acid into D(-)-.beta.-hydroxyisobutyric acid in an aqueous medium, and D(-)-.beta.-hydroxyisobutyric acid is recovered from the aqueous medium.

Abstract: A process is disclosed wherein yeast cells containing coenzyme Q in large quantities are efficiently produced by aerobically cultivating a yeast, in which maximum specific growth rate is not less than 0.15 hr.sup.-1 under optimum cultural conditions, in a nutrient medium in which said yeast can grow, while maintaining the dissolved oxygen concentration in the culture broth at not less than 2 ppm and controlling the average specific growth rate through the whole period of cultivation at not more than 0.1 hr.sup.-1, and coenzyme Q is recovered from the resulting yeast cells.